Androgen Receptor Sensitivity: Why Same DHT Levels Hit Men Differently

Serum DHT explains less about AGA severity than most people assume. Androgen receptor polymorphisms at the follicle level — not the DHT reading on a blood panel — determine who goes bald and how fast.

The clinical question of why brothers raised in the same household, eating the same food, with similar serum DHT levels can have dramatically different AGA severity is answered not by the DHT level but by the androgen receptor — specifically, how sensitively each man's follicle DP cells respond to that DHT.

The receptor determines the response

Androgen receptors in follicle dermal papilla cells are encoded by the AR gene on the X chromosome. The receptor protein, once bound by DHT, undergoes conformational change, dimerises, and acts as a transcription factor driving the downstream gene expression changes that shorten anagen. The efficiency of this entire process — binding, conformational change, transcriptional activation — varies between men based on AR gene polymorphisms.

The most studied polymorphism is the CAG repeat in exon 1 of the AR gene, which encodes a polyglutamine stretch in the N-terminal domain of the receptor. Shorter CAG repeats correlate with higher AR transcriptional activity; longer repeats correlate with lower activity. A man with a short CAG repeat has a more transcriptionally active androgen receptor in his follicle DP cells and consequently more aggressive AGA for a given DHT level than a man with a longer repeat.

Follicle-level vs systemic AR expression

The androgen receptor is expressed throughout the body — in muscle, prostate, liver, brain, and skin. The AR genotype affects receptor activity across all these tissues, not just in follicles. But the follicle-level consequence of high AR activity is AGA; the systemic consequences include differences in muscle anabolism, libido, and prostate sensitivity. This co-inheritance explains why AGA-prone men may also have other androgen-related phenotypic traits.

Implications for treatment

High AR sensitivity has two implications for treatment. First, even deeply suppressed DHT (dutasteride-level suppression to approximately 5–10% of baseline) may drive some follicle response in very high AR-sensitivity individuals. Second, anti-androgen approaches — compounds that directly block AR at the follicle level rather than reducing DHT — are theoretically more effective in high-sensitivity individuals. Clascoterone (topical AR antagonist) targets this mechanism directly and is in late-stage development for AGA.